Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael E Rothenberg

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Clinical Drug Investigation|July 25, 2019
Correction to: Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel Na<sub>V</sub>1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy VolunteersMichael E Rothenberg, Michael Tagen, Jae H Chang, et al.
Clinical Drug Investigation|June 8, 2019
Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel Na<sub>V</sub>1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy VolunteersMichael E Rothenberg, Michael Tagen, Jae H Chang, et al.
Gut|February 2, 2023
Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitisFrank Wagner, John C Mansfield, Annemarie N Lekkerkerker, et al.
Nature Methods|October 22, 2013
Quantitative assessment of single-cell RNA-sequencing methodsAngela R Wu, Norma F Neff, Tomer Kalisky, et al.
Gastroenterology|June 1, 2015
KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon CancersEvan C Chen, Taylor A Karl, Tomer Kalisky, et al.
Microbiome|March 9, 2023
IL-22 alters gut microbiota composition and function to increase aryl hydrocarbon receptor activity in mice and humansJordan S Mar, Naruhisa Ota, Nick D Pokorzynski, et al.
Nature Cell Biology|June 26, 2019
R-spondin-3 induces secretory, antimicrobial Lgr5<sup>+</sup> cells in the stomachMichael Sigal, Maria Del Mar Reinés, Stefanie Müllerke, et al.
Science Translational Medicine|December 20, 2023
Inhibition of RIP1 improves immune reconstitution and reduces GVHD mortality while preserving graft-versus-leukemia effectsMariano Prado-Acosta, Seihwan Jeong, Alberto Utrero-Rico, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2016
Control of inflammation by stromal Hedgehog pathway activation restrains colitisJohn J Lee, Michael E Rothenberg, E Scott Seeley, et al.
Clinical and Translational Science|August 19, 2023
A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteersNicholas S Jones, Smita Kshirsagar, Vishnu Mohanan, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Clinical Drug Investigation|July 25, 2019
Correction to: Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel Na<sub>V</sub>1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy VolunteersMichael E Rothenberg, Michael Tagen, Jae H Chang, et al.
Clinical Drug Investigation|June 8, 2019
Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel Na<sub>V</sub>1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy VolunteersMichael E Rothenberg, Michael Tagen, Jae H Chang, et al.
Gut|February 2, 2023
Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitisFrank Wagner, John C Mansfield, Annemarie N Lekkerkerker, et al.
Nature Methods|October 22, 2013
Quantitative assessment of single-cell RNA-sequencing methodsAngela R Wu, Norma F Neff, Tomer Kalisky, et al.
Gastroenterology|June 1, 2015
KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon CancersEvan C Chen, Taylor A Karl, Tomer Kalisky, et al.
Microbiome|March 9, 2023
IL-22 alters gut microbiota composition and function to increase aryl hydrocarbon receptor activity in mice and humansJordan S Mar, Naruhisa Ota, Nick D Pokorzynski, et al.
Nature Cell Biology|June 26, 2019
R-spondin-3 induces secretory, antimicrobial Lgr5<sup>+</sup> cells in the stomachMichael Sigal, Maria Del Mar Reinés, Stefanie Müllerke, et al.
Science Translational Medicine|December 20, 2023
Inhibition of RIP1 improves immune reconstitution and reduces GVHD mortality while preserving graft-versus-leukemia effectsMariano Prado-Acosta, Seihwan Jeong, Alberto Utrero-Rico, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2016
Control of inflammation by stromal Hedgehog pathway activation restrains colitisJohn J Lee, Michael E Rothenberg, E Scott Seeley, et al.
Clinical and Translational Science|August 19, 2023
A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteersNicholas S Jones, Smita Kshirsagar, Vishnu Mohanan, et al.
Pageof 3